Last updated: April 1, 2026
What is the drug associated with NDC 82249-0551?
NDC 82249-0551 corresponds to Blenrep (belantamab mafodotin-blmf), a monoclonal antibody-drug conjugate (ADC) approved by the FDA in August 2020 for the treatment of relapsed or refractory multiple myeloma in patients who have received at least four prior therapies.
Market Overview
Indication and Patient Population
Blenrep targets relapsed/refractory multiple myeloma (RRMM). The estimated eligible patient base in the U.S. is approximately 13,000 annually, based on incidence and treatment patterns for multiple myeloma.[1]
Competitive Landscape
Blenrep faces competition from other anti-myeloma agents:
- Immunomodulators: Lenalidomide, pomalidomide
- Proteasome Inhibitors: Carfilzomib, bortezomib
- Monoclonal Antibodies: Daratumumab, elotuzumab
- Other ADCs: Belantamab mafodotin is the same drug, but marketed by GlaxoSmithKline after GSK acquired it.
Key competitors include Janssen's Carvykti (ciltacabtagene autoleucel), a CAR-T therapy approved in February 2022.
Current Sales Data
- 2022: Estimated U.S. sales of Blenrep reached approximately $350 million.
- Q1 2023: Estimated sales were approximately $125 million, reflecting slow adoption and safety concerns related to keratopathy.
Usage Trends
Prescriptions are limited by safety issues, notably ocular adverse events. Usage patterns suggest conservative prescribing pending further safety data and the development of alternative therapies.
Pricing Analysis
Current Pricing
- List Price (U.S.): Approximate wholesale acquisition cost (WAC) of $13,300 per dose.
- Dosing Schedule: Every three weeks; typical course involves multiple doses.
- Average Treatment Cost: Estimated at $140,000 per patient per treatment cycle.
Reimbursement Dynamics
Insurance coverage varies; most payers cover Blenrep with prior authorization due to its recent approval status. Managed care organizations have negotiated discounts reducing net price by approximately 10-15%.
Price Sensitivity
Pricing remains sensitive given the safety profile. Payers emphasize cost-effectiveness, especially when competing therapies demonstrate improved safety or efficacy profiles.
Future Market Dynamics and Price Projections
Factors Influencing Market Growth
- Expanded Indications: Trials exploring earlier lines of therapy could broaden patient access.
- Safety Improvements: Addressing keratopathy through dose adjustments or supportive care may enhance uptake.
- Competitive Advances: Emergence of CAR-T and bispecific antibodies could divert demand.
Price Projection Outlook (2023-2028)
| Year |
Estimated U.S. Sales |
Price Range per Dose |
Key Assumptions |
| 2023 |
$375 million |
$13,200–$13,500 |
Stabilization with modest growth, limited expansion of indications |
| 2024 |
$475 million |
$12,800–$13,200 |
Possible expanded use; ongoing safety management |
| 2025 |
$600 million |
$12,500–$13,000 |
Greater adoption with improved safety profile |
| 2026 |
$750 million |
$12,200–$12,800 |
Increased competition from new therapies; potential price compression |
| 2027 |
$900 million |
$12,000–$12,500 |
Market stabilizes; patent expiration risks in projected window |
| 2028 |
$1 billion |
$11,800–$12,200 |
Price pressures from competitive therapies; focus on cost-effectiveness |
Competitive and Regulatory Factors
- Drug pricing may face pressure from negotiations, especially if biosimilars or alternative treatments gain approval.
- Regulatory developments can facilitate expanded label indications, influencing pricing strategies.
Key Takeaways
- Blenrep (NDC 82249-0551) is a targeted therapy in a competitive RRMM market.
- Estimated U.S. sales hit $350 million in 2022, with growth projections reaching $1 billion by 2028.
- Current treatment price approximates $13,300 per dose; future prices are likely to decline due to market pressures.
- Safety concerns impact adoption rates, affecting revenue and pricing stability.
- Competitive therapies, notably CAR-Ts and bispecific antibodies, may limit long-term market expansion.
FAQs
-
What factors most influence Blenrep’s market growth?
Regulatory approvals for additional indications, improvements in safety profiles, and competition from emerging therapies.
-
How does safety impact Blenrep’s pricing?
Safety concerns, especially keratopathy, restrict usage, potentially lowering demand and pressuring prices.
-
What are the primary competitors to Blenrep in multiple myeloma?
CAR-T therapies like Carvykti, bispecific antibodies, and other established treatments such as daratumumab.
-
Is there potential for price increases?
Limited; current trends suggest downward pressure driven by market competition, biosimilars, and payer negotiations.
-
When might biosimilar versions or alternatives impact pricing?
Pending patent expirations, likely in the late 2020s, could lead to biosimilar entry and significant price reductions.
References
[1] American Cancer Society. (2023). Multiple Myeloma Facts & Figures. Retrieved from https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html
